Wall Street analysts forecast that Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will report earnings per share of $0.22 for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Amphastar Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.23 and the lowest estimate coming in at $0.20. Amphastar Pharmaceuticals reported earnings per share of $0.15 in the same quarter last year, which would suggest a positive year-over-year growth rate of 46.7%. The business is scheduled to report its next earnings report on Friday, November 5th.
On average, analysts expect that Amphastar Pharmaceuticals will report full-year earnings of $0.95 per share for the current fiscal year, with EPS estimates ranging from $0.91 to $0.99. For the next fiscal year, analysts expect that the company will report earnings of $1.26 per share, with EPS estimates ranging from $1.16 to $1.34. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Sunday, August 8th. The company reported $0.21 EPS for the quarter, meeting analysts’ consensus estimates of $0.21. Amphastar Pharmaceuticals had a return on equity of 8.01% and a net margin of 2.72%.
Amphastar Pharmaceuticals stock traded up $0.44 during midday trading on Friday, reaching $18.37. 486,558 shares of the stock traded hands, compared to its average volume of 200,029. The company has a 50-day simple moving average of $19.65 and a two-hundred day simple moving average of $19.07. Amphastar Pharmaceuticals has a 12-month low of $16.91 and a 12-month high of $21.63. The firm has a market cap of $882.35 million, a PE ratio of 87.48 and a beta of 0.74. The company has a current ratio of 2.50, a quick ratio of 1.71 and a debt-to-equity ratio of 0.07.
In related news, EVP Rong Zhou sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, July 26th. The stock was sold at an average price of $20.87, for a total transaction of $125,220.00. Following the completion of the sale, the executive vice president now owns 92,244 shares in the company, valued at $1,925,132.28. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO William J. Peters sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 7th. The stock was sold at an average price of $20.37, for a total value of $203,700.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,711 shares of company stock valued at $1,066,412. 28.40% of the stock is owned by company insiders.
Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 3.3% in the first quarter. BlackRock Inc. now owns 7,377,178 shares of the company’s stock valued at $135,150,000 after purchasing an additional 233,012 shares during the period. Federated Hermes Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 6.7% in the first quarter. Federated Hermes Inc. now owns 3,441,367 shares of the company’s stock valued at $63,046,000 after purchasing an additional 215,484 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Amphastar Pharmaceuticals by 0.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,695,893 shares of the company’s stock valued at $34,189,000 after purchasing an additional 6,804 shares during the period. State Street Corp increased its holdings in shares of Amphastar Pharmaceuticals by 2.5% in the second quarter. State Street Corp now owns 1,439,931 shares of the company’s stock valued at $29,029,000 after purchasing an additional 34,978 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 17.4% in the second quarter. Goldman Sachs Group Inc. now owns 844,062 shares of the company’s stock valued at $17,017,000 after purchasing an additional 125,180 shares during the period. 56.53% of the stock is currently owned by institutional investors and hedge funds.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs.
Further Reading: Why does the United States have a lingering trade deficit?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.